These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25387822)

  • 21. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
    Russo V; Rago A; Papa AA; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2018 Feb; 45(2):206-212. PubMed ID: 29260427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre.
    Schiavoni M; Margaglione M; Coluccia A
    Blood Transfus; 2018 Feb; 16(2):209-214. PubMed ID: 28287377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.
    Paquette M; Riou França L; Teutsch C; Diener HC; Lu S; Dubner SJ; Ma CS; Rothman KJ; Zint K; Halperin JL; Huisman MV; Lip GYH; Nieuwlaat R
    J Am Coll Cardiol; 2017 Sep; 70(13):1573-1583. PubMed ID: 28935034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
    Lip GYH; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Phatak H
    PLoS One; 2018; 13(4):e0195950. PubMed ID: 29709012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 35. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
    Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
    Chan PH; Huang D; Hai JJ; Li WH; Yin LX; Chan EW; Wong IC; Lau CP; Chiang CE; Zhu J; Tse HF; Siu CW
    Heart Rhythm; 2016 Feb; 13(2):366-73. PubMed ID: 26392326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
    J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
    Fukaya H; Niwano S; Oikawa J; Nishinarita R; Horiguchi A; Nakamura H; Fujiishi T; Igarashi T; Ishizue N; Yoshizawa T; Satoh A; Kishihara J; Murakami M; Ako J
    J Cardiol; 2017 Mar; 69(3):591-595. PubMed ID: 27377855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.